1. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150(9):1405-1407.

2. Andersson U, Häggström JE, Levi ED, Bondessan U, Valverius M, Gunne LM. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Movement Disord 1989;4:37-46.

3. Baldessarini RJ, Cole JO, Davis JM, Gardos G, Preskorn SH, Simpson GM, Tarsy D. Tardive dyskinesia: a task force report. Washington, DC: American Psychiatric Press, 1980.

4. Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia. Shortened left caudate T2. Biol Psychiatry 1990;28:1027-1036.

5. Benes FM, Pashevich PA, Davidson J, Domesick VB. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 1985;329:265-273.

6. Bleuler E. Dementia praecox or the group of schizophrenias. New York: International Universities Press, 1950.

7. Bunney BS, Sesack SR, Silva N. Midbrain dopaminergic systems: neurophysiology and electrophysiological pharmacology. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;113-126.

8. Burt DR, Creese I, Synder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in the brain. Science 1977;196:326-328.

9. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-108.

10. Casey DE. Tardive dyskinesia—animal models. Psychopharmacol Bull 1984;20:376-379.

11. Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985;46:42-47.

12. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven, 1987;1411-1419.

13. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:S47-S53.

14. Casey DE. Tardive dyskinesia. West J Med 1990;153:535-541.

15. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Dunner DL, ed. The psychiatric clinics of North America. Psychopharmacology I, vol 16, part 3. Philadelphia: WB Saunders, 1993;589-610.

16. Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology 1977;54:1-8.

17. Casey DE, Gerlach J, Magelund G, Rosted Christensen T. The effect of gamma-acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376-1379.

18. Christensen AV, Fjalland B, Moller Nielsen I. On the supersensitivity of dopamine receptors induced by neuroleptics. Psychopharmacology 1976;48:1-6.

19. Christensen E, Moller JE, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970;46:14-23.

20. Clow A, Jenner P, Marsden CD. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol 1979;57:365-375.

21. Coward DM, Imperato A, Urwyler S, White TG. Biochemical and behavioural properties of clozapine. Psychopharmacology 1989; 99:S6-S12.

22. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Johnstone EC, Owen F, Owens DGC, Poulter M. Chemical and structural changes in the brain in patients with movement disorder. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia: research and treatment. Berlin: Springer-Verlag, 1985;104-110.

23. Crow TJ, Cross AJ, Johnstone EC, Owens DG, Waddington JL. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 1982;2:336-340.

24. Ellison G, See RE. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology 1989;98:564.

25. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine—relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.

26. Fibiger HC, Lloyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurol Sci 1984;7:462-464.

27. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 1980;283:569-570.

28. Ganzini L, Heintz R, Hoffman W, Casey DE. Prevalence of tardive dyskinesia in neuroleptic treated diabetics. Arch Gen Psychiatry 1991;48:259-263.

29. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.

30. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988;77:369-378.

31. Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacology 1974;34:21-35.

32. Glazer WM. Noradrenergic function and tardive dyskinesia. Psychiatr Ann 1989;19(6):297-301.

33. Gunne LM, Andersson U, Bondesson U, Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986;25:897-901.

34. Gunne LM, Barany S. Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 1976;50:237-240.

35. Gunne LM, Häggström JE. Pathophysiology of tardive dyskinesia. In: Casey DE, Chase T, Christensen AV, Gerlach J, eds. Dyskinesia: research and treatment. Berlin: Springer, 1985;191-193.

36. Gunne LM, Häggström JE, Sj`quist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347-349.

37. Häggström JE. Bromocriptine in the treatment of tardive dyskinesia—an update. Integr Psychiatry 1989;6:171-179.

38. Hoffman WF, Casey DE. Computed tomographic evaluation of patients with tardive dyskinesia. Schizophr Res 1991;5:1-12.

39. Hunter R, Blackwood W, Smith MC. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 1968;7:263-273.

40. Jeste DV, Lohr JB, Kaufmann CA, Wyatt RJ. Pathophysiology of tardive dyskinesia: evaluation of supersensitivity theory and alternative hypotheses. In: Casey DE, Gardos G, eds. Tardive dyskinesia and neuroleptics: from dogma to reason. Washington, DC: American Psychiatric Press, 1986;15-32.

41. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry 1982;39:803-816.

42. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtieri CT, Schooler NR, Sprague RL, Wettstein RM. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.

43. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacol Bull 1984;20:39-40.

44. Kaufmann CA, Jeste DV, Shelton RC. Noradrenergic and neuroradiologic abnormalities in tardive dyskinesia. Biol Psychiatry 1986;21:799-812.

45. Klawans HL, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972;33:235-246.

46. Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl-GABA in tardive dyskinesia. Psychiatry Res 1983;8:261-269.

47. Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB. The effect of tetrahyroisoxazolopyridinol (THIP) in tardive dyskinesia. Arch Gen Psychiatry 1982;39:1017-1021.

48. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: E and S Livingstone, 1919.

49. Lieberman J, Kane JM, Woerner M. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984;20:22-26.

50. Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991;48:1097-1106.

51. Lohr JB, Cadet JL, Lohr MA, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988;14:291-296.

52. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry 1990;28:535-539.

53. Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B. Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. Neuropsychopharmacology 1992;7(4):285-293.

54. Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology 1992;106:45-52.

55. Mithani S, Atymadja A, Bainbridge KG, Fibiger HC. Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology 1987;93:94-100.

56. Mukherjee S, Roth SD, Sandyk R, Schnur DB. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 1989;29:17-27.

57. Nielsen EB, Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (Flupenthixol) in rats. Psychopharmacology 1978;59:85-89.

58. Peet M, Laugharne J, Rangarajan N, Reynolds GP, Watson REB, Cutts AJ. Tardive dyskinesia, lipid peroxidation and vitamin E. Schizophr Res 1993;9(2,3):279.

59. Richardson MA, Suckow R, Whittaker R, et al. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia. Psychopharmacol Bull 1989;25:47-51.

60. Rupniak NMJ, Jenner P, Marsden CD. Cholinergic manipulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 1983;79:226-230.

61. Rupniak NMJ, Prestwick SA, Horton RW, Jenner P, Marsden CD. Alterations in cerebral glutamic acid decarboxylase and [3H]-flunitrazepam binding during continuous treatment of rats for one year with haloperidol, sulpiride, or clozapine. J Neurol Transm 1987;68:113-125.

62. Saltz BL, Woerner M, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406.

63. Scheel-Kruger J, Arnt J. New aspects on the role of dopamine, acetylcholine and GABA in the development of tardive dyskinesia. In: Casey DE, Chase T, Christensen AV, Gerlach J, eds. Dyskinesia: research and treatment. Berlin: Springer-Verlag, 1985;19-30.

64. Schelkunov EL. Adrenergic effect of chronic administration of neuroleptics. Nature 1967;214:1210-1212.

65. Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992;149:391-393.

66. Stahl SM, Faull KF, Barchas JD, Berger PA. CSF monoamine metabolites in movement disorders and normal aging. Arch Neurol 1985;42:166-169.

67. Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry 1979;36:595-598.

68. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioral supersensitivity to apomorphine. Nature 1973;245:262-263.

69. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-451.

70. Thaker GK, Tamminga CA, Alphs LA, Lafferman J, Ferraro TN, Hare TA. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Arch Gen Psychiatry 1987;44:522-529.

71. Waddington JL. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int Rev Neurobiol 1989;31:297-353.

72. Waddington JL. Implications of recent research on dopamine D1 and D2 receptor subtypes in relation to schizophrenia and neuroleptic drug action. Neurosci Neuropsychiatry 1989;2:89-92.

73. Waddington JL, Cross AJ, Gamble SJ, Bourne RC. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 1983;220:530-532.

74. Waddington JL, Youssef HA. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Br J Psychiatry 1990;156:106-108.

75. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine cells. Science 1983;221:1054-1057.

76. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993;150(6):966-968.

Back to Chapter